Roteas Union européenne - slovène - EMA (European Medicines Agency)

roteas

berlin-chemie ag - edoxaban tosilate - stroke; venous thromboembolism - antitrombotična sredstva - preprečevanje možgansko kap in sistemsko embolijo pri odraslih bolnikih z nonvalvular atrijsko fibrilacijo (nvaf) z eno ali več dejavniki tveganja, kot so kongestivno srčno popuščanje, hipertenzijo, starost ≥ 75 let, sladkorna bolezen, predhodna kap ali prehodnih ishemičnih napad ( tia). zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih.

Calquence Union européenne - slovène - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - levkemija, limfocitna, kronična, b-celica - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Dabigatran Etexilate Accord Union européenne - slovène - EMA (European Medicines Agency)

dabigatran etexilate accord

accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - antitrombotična sredstva - prevention of venous thromboembolic events.